P033 Cutaneous adverse drug reaction due to apixaban

Albalbissi, A.; Balagoni, Harika; Treece, Jennifer; Balbissi, K. Al; Gonzalez‐Estrada, Alexei

doi:10.1016/j.anai.2017.08.102

Cited by 3 publications

(2 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…No biopsy was performed and patch testing with apixaban, rivaroxaban, and edoxaban was negative; however, challenge was declined, and the patient was treated successfully with warfarin instead. 20 A case of apixaban-induced leukocytoclastic vasculitis manifesting as erythematous rash on lower limbs quickly progressing to purpuric itchy and burning rash, developed 10 days after drug exposure. Histopathology of skin biopsy revealed infiltration of neutrophils around and inside the superficial vascular plexus together with focal fibrinoid vessel wall necrosis in association with erythrocyte extravasation.…”

Section: Discussionmentioning

confidence: 99%

A rare case report of apixaban-induced lichenoid eruption

Patil

Hanna

Torre

2020

Therapeutic Advances in Drug Safety

View full text Add to dashboard Cite

With recent increase in the use of direct oral anticoagulants (DOACs), several new cases of adverse drug reactions (ADRs) have been identified in pharmacovigilance surveys. These ADRs can result in significant mortality and morbidity if not identified and treated promptly. It is important for physicians to recognize that immunologically mediated delayed hypersensitivity reactions, although rare in occurrence, can have significant impact on patient’s quality of life. To the best of our knowledge, we report the first case of lichenoid eruption associated with apixaban. We further provide evidence of tolerance to rivaroxaban in the same patient. Plain language summary Apixaban-induced lichenoid eruption Well documented case reports, although providing evidence of probable causal relationship between a drug and specific adverse drug reactions (ADRs), can increase awareness amongst clinicians treating patients with direct oral anticoagulants (DOACs), especially with its rapid utilization. Rare ADRs are difficult to detect as clinical trials of DOACs lacked enough patient sample, making post-marketing reporting of such events important so both patients and clinicians can be vigilant to help with prompt recognition of such symptoms. We report the first case of lichenoid eruption hypersensitivity reaction associated with apixaban in patient with tolerance to rivaroxaban.

show abstract

Section: Discussionmentioning

confidence: 99%

A rare case report of apixaban-induced lichenoid eruption

Patil

Hanna

Torre

2020

Therapeutic Advances in Drug Safety

View full text Add to dashboard Cite

show abstract

“…Two patient cases were identified that reported adverse drug reactions associated with apixaban. In one case, patient experience cutaneous adverse drug reaction secondary to apixaban leading to cessation of the medication [ 31 ]. In the other case, patient experienced angioedema with significant laryngeal edema without presence of urticaria or pruritis [ 32 ].…”

Section: Discussionmentioning

confidence: 99%

A Case Report of Rivaroxaban-Induced Urticaria and Angioedema With Possible Cross-Reaction to Dabigatran

Patil

Ikekwere

2019

J Med Cases

View full text Add to dashboard Cite

Anticoagulants are commonly associated with hemorrhagic complications. However, rare hypersensitivity drug reactions associated with direct oral anticoagulants (DOACs) in form of cutaneous reactions such as urticaria as well as angioedema can have significant burden owing to increase in morbidity and mortality. Angioedema can be allergic, hereditary or idiopathic and can occur in isolation, in combination with urticaria as contributing component of anaphylaxis. With increase in the use of DOACs over warfarin as choice of anticoagulant in the treatment of atrial fibrillation (AF) as well as venous thromboembolism (VTE), recent post marketing surveillance has identified several reports of adverse drug reactions. This case report describes the clinical course of patient being treated for VTE, who experienced rivaroxaban-induced urticaria and angioedema. We further provide evidence for cross-reactivity to dabigatran manifested as significant cutaneous reaction. Patient was transitioned to warfarin with enoxaparin bridge and tolerated it well without any complications.

show abstract

Apixaban

2018

Reactions Weekly

View full text Add to dashboard Cite

P033 Cutaneous adverse drug reaction due to apixaban

Cited by 3 publications

References 0 publications

A rare case report of apixaban-induced lichenoid eruption

A rare case report of apixaban-induced lichenoid eruption

A Case Report of Rivaroxaban-Induced Urticaria and Angioedema With Possible Cross-Reaction to Dabigatran

Apixaban

Contact Info

Product

Resources

About